Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Milestones Administradora de Recursos Ltda.

Milestones Administradora de Recursos Ltda. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 50.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,465 shares of the medical research company's stock after selling 7,460 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.8% of Milestones Administradora de Recursos Ltda.'s portfolio, making the stock its 13th biggest position. Milestones Administradora de Recursos Ltda.'s holdings in Thermo Fisher Scientific were worth $4,618,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Signature Resources Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares during the period. New Millennium Group LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $29,000. Stephens Consulting LLC increased its position in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after acquiring an additional 29 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter valued at $32,000. Finally, Bank & Trust Co purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at $33,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Bank of America lifted their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, Bernstein Bank lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares of the company's stock, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,300 shares of company stock worth $6,831,268 in the last quarter. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $2.66 during trading on Wednesday, hitting $550.43. The company had a trading volume of 1,452,160 shares, compared to its average volume of 1,466,484. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a fifty day simple moving average of $602.70 and a two-hundred day simple moving average of $583.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $433.15 and a fifty-two week high of $627.88. The firm has a market capitalization of $210.26 billion, a price-to-earnings ratio of 34.35, a price-to-earnings-growth ratio of 3.66 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the firm earned $5.69 earnings per share. The business's revenue was up .2% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.